Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
Objective The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin‐1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis or ma...
Main Authors: | Luke Adam Monteagudo, Aaron Boothby, Elie Gertner |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-05-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11135 |
Similar Items
-
Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019
by: Theresa L. Wampler Muskardin
Published: (2020-05-01) -
Intravenous administration of anakinra in children with macrophage activation syndrome
by: Omkar Phadke, et al.
Published: (2021-06-01) -
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
by: Annette Langer-Gould, et al.
Published: (2020-10-01) -
Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome
by: Olha Halyabar, et al.
Published: (2019-02-01) -
Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19
by: Angela E. Peter, et al.
Published: (2021-01-01)